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Response to Letter by Pilz et al
Response:
While our work passed through the peer-review process for
publication in Stroke, Pilz et al published data demonstrating an
inverse and independent correlation between adiponectin levels
and carotid intima-media thickness (IMT).1 In this work, the
authors compared 140 obese juveniles (mean age 13.54.4
years) with 100 age-matched, healthy, normal-weight controls
and demonstrated a significant negative correlation between
serum adiponectin levels and carotid IMT, even after controlling
for common cardiovascular risk factors. The authors do not
report the numbers of males and females, respectively, in their
study population. In our study we investigated the association
between plasma adiponectin levels and sonographic phenotypes
of subclinical atherosclerosis, which may represent different
stages of disease as well as common and distinct determinants.2
Thus, our work focused not only on the association between
adiponectin levels and IMT, but we investigated the association
of this biomarker with different stages of atherosclerosis. Fur-
thermore, our study population represents a healthy, middle-
aged, white population with a mean body mass index of 26.7 and,
therefore, differs substantially from the population of Pilz et al.
Our results demonstrate an inverse correlation between adi-
ponectin levels and IMT, thus confirming the observation that
early stages of atherosclerosis, as defined by an increased IMT,
are associated with hypoadiponectinemia. In addition, our results
failed to demonstrate an association between adiponectin levels
and advanced stages of atherosclerosis as represented by the
presence of plaques. Earlier studies demonstrated a stronger
impact of adiponectin on atherosclerosis and clinical end points
almost exclusively in men.3–5 These data are supported by our
results, which demonstrate a stronger impact of hypoadi-
ponectinemia on IMT in men. The lack of an association between
adiponectin levels and the risk of coronary artery disease in
women, as demonstrated recently,6 is consistent with these data.
The results of Lindsay and colleagues7 suggest that adiponectin
is not an independent risk factor for coronary artery disease and
that its role is more important in insulin resistance and diabetes.
These results were found in a diabetic and obese population of
volunteers of American Indian heritage, which differs substan-
tially from our study population, thus suggesting that differences
in the results between studies may be explained by underlying
differences in the study populations. Furthermore, the cross-
sectional design of our study warrants cautious interpretation of
the results, and we agree with Pilz and colleagues that further
investigations are necessary to substantiate the definitive diag-
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